Onkologicky Ustav Sv Alzbety s.r.o.

The site is conducting studies focused on advanced and early-stage breast cancer, aiming to improve outcomes with novel endocrine and targeted combinations.

• Testing PI3K inhibition alongside HER2‑directed therapy
• Comparing CDK4/6 inhibitor regimens for hormone‑receptor positive disease
• Evaluating antibody‑drug conjugate sacituzumab govitecan in triple‑negative cases

These trials involve seven investigators at the Bratislava hospital, contributing to the European oncology network.

Research at Onkologicky Ustav Sv Alzbety includes studies of metastatic castration‑resistant prostate cancer, seeking safer and more effective treatment options.

• Assessing a novel oral agent combined with enzalutamide
• Exploring safety of the agent as monotherapy in advanced disease

The investigations are part of a broader effort to expand therapeutic choices for men with advanced prostate tumors.

Trials target BRAF V600E‑mutant metastatic colorectal cancer, evaluating targeted combinations to overcome resistance.

• Comparing encorafenib plus cetuximab with or without chemotherapy
• Studying safety of a multi‑kinase inhibitor across solid tumors

Findings aim to refine precision medicine strategies for patients with this genetic alteration.

A series of early‑phase investigations examine a new selective inhibitor in various cancers, including NSCLC, liposarcoma, and tumors with CDK4/CCND1 amplification.

• Determining maximum tolerated dose and recommended phase 2 dose
• Evaluating drug‑drug interactions with standard endocrine agents
• Assessing food effect on pharmacokinetics

The research supports the development of versatile therapies that may benefit multiple tumor types.